Regent Pacific Group
Finance · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Henley Bldg 5 Queen's Rd Central Fl 8, C...Phone Number
(949) 786-8628Website
www.regentpac.comRevenue
<$5 MillionStock Symbol
575Industry
About Regent Pacific Group
Regent Pacific Group Org Chart
Is Regent Pacific Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Regent Pacific Group has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Regent Pacific Group has new funding data
Website visits: Recent activity has been detected on your website
Regent Pacific Group, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Regent Pacific Group had a recent Job posting/layoffs
Earning: See what the market has to say on Regent Pacific Group recently announced quarterly report
Product Launch: Get notified when Regent Pacific Group launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Regent Pacific Group is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Regent Pacific Group
Recommended Actions
Reach out to Masked Content who joined Regent Pacific Group as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Regent Pacific Group is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Regent Pacific Group is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Regent Pacific Group.
Regent Pacific Group Tech Stack
A closer look at the technologies used by Regent Pacific Group
Regent Pacific Group News & Media
Regent Pacific's Unrealised Gain in Venturex Resources Limited Increased to US$10.74 million
Highlights: Unrealised Gain in Venturex Resources Limited Regent Pacific's investment in Venturex Resources Limited has increased significantly to US$10.74 million (approximately HK$83.77 million) and a marked to-market value of US$13.13 million (approximately HK$102.41million) on its VXR shareholding, representing a 450% increase from 31 December 2020. Venturex Resources Limited ("VXR"), Regent Pacific's investment announced a recapitalisation plan which aims at resetting the company for growthRegent Pacific Receives HK$24.96 million After Clinical Trial Approval For FORTACIN(TM) Has Been Obtained
HONG KONG, April 1, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that the Group has received a payment of US$3.20 million (approximately HK$24.96 million) before deduction of PRC withholding tax in full on 31 March 2021 from Wanbang Biopharmaceutical Group Co., Ltd. (Wanbang Biopharmaceutical), tDeep Longevity Publishes Article About Preventing COVID-19 and Aging
HONG KONG, Feb. 16, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK: 0575.HK)'s Deep Longevity, Inc, a company acquired on 14 December 2020 which develops artificial intelligence to track human aging and extend productive longevity, today announced the publication of an article in Lancet Healthy Aging titled "The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severiRegent Pacific's Strategic Partner Obtains Clinical Trial Approval for FORTACIN(TM)
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Biopharmaceutical Group Co., Ltd. (Wanbang Biopharmaceutical), the Company's commercial strategic partner for China, obtained Clinical Trial Approval ("CTA") for Senstend™ (the marketing name of Fortacin™ in China) from
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regent Pacific Group
Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 23 years of financial reporting sinc... Read More